A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia
Status:
Completed
Trial end date:
2017-01-05
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to investigate the efficacy of repeat oral dosing of
BIIB074 on paroxysmal pain in participants with Primary Inherited Erythromelalgia (EM). The
secondary objective of the study is to investigate the efficacy of repeat oral dosing of
BIIB074 on varying additional aspects of pain in participants with EM; and to investigate the
safety and tolerability of repeat oral dosing of BIIB074 in participants with EM.